KC
KTTA icon

Kepos Capital’s Pasithea Therapeutics KTTA Stock Holding History

Kepos Capital’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$1.22M – 654
2021
Q3 		$1.22M Buy
+20,000
New +$1.21M 0.08% 283

Other funds holding KTTA

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kepos Capital's KTTA Position: Q4 2021 in Review

Kepos Capital sold out of Pasithea Therapeutics (KTTA) in Q4 2021, closing a stake of 20,000 shares — an estimated $1.22M sold.

Kepos Capital first reported a position in KTTA in Q3 2021 and held it in 1 quarter. The position peaked at $1.22M in Q3 2021. 7 funds tracked by Wall St. Rank hold KTTA as of Q4 2021.

  • Kepos Capital reported no remaining Pasithea Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Kepos Capital sold 20,000 Pasithea Therapeutics shares in Q4 2021, an estimated $1.22M.
  • Kepos Capital first reported a position in Pasithea Therapeutics in Q3 2021 and held it in 1 quarter.
  • Kepos Capital's Pasithea Therapeutics position peaked at $1.22M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2021.

Based on Kepos Capital's 13F filing for Q4 2021, filed 14 Feb 2022.